Clinical trial of technetium-99 methylenediphosphonate injection in the treatment of senile osteoporotic fracture and osteoarthriti
10.13699/j.cnki.1001-6821.2017.19.009
- VernacularTitle:99锝亚甲基二膦酸盐注射液治疗老年骨质疏松性骨折和骨关节炎的临床研究
- Author:
Dong-Ming ZHOU
1
;
De-Guo LIU
;
Zhen-Hai HOU
Author Information
1. 中国人民解放军第一一七医院骨科
- Keywords:
technetium-99 methylenediphosphonate;
osteoporosis;
fracture;
osteoarthritis
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(19):1882-1885
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical effect of technetium-99 methylenediphosphonate injection (99Tc-MDP)in treatment of senile osteoporotic fracture and osteoarthriti.Methods A total of 120 cases of osteoporotic fracture or osteoarthritis were randomly divided into the control group (n =60) and the treatment group (n =60).The patients in control group were given 8-week treatment of intra-articular injection of sodium hyaluronate injection (25 mg,once a week) and betamethasone sodium phosphate injection (7 mg,once a week);In the meantime,the patients also received oral calcium carbonate D3 (600 mg,once daily) and alfacalcidol capsules (0.25 g,once daily) for 6 months;the treatment group received 10-day course of intravenous infusion of 99Tc-MDP (15 mg,once daily) for 4 courses (with 30 days of intervals between courses).After a 6-month follow-up,the clinical efficacy of two groups was compared,and the effect of different treatment on L1 ～ L4 bone mineral density (BMD)value,serum bone alkaline phosphatase (BALP) and 25-hydroxy vitamin D3 25-(OH) D3 level;procollagen Ⅰ N-terminal propeptide (PINP) and bone glaprotein (BGP) and type Ⅰ collagen carboxy terminal peptide (CTX) content were compared between two groups and the occurrence of adverse drug reactions were recorded.Results After treatment,the total effective rate of the treatment group and the control group was 91.67％ (55/60 cases) and 78.33％ (47/60 cases),respectively,the difference was statistically significant (P ＜0.05).After treatment,the BMD of L1 ～4 in the treatment group were (0.94 ±0.15),(0.98 ±0.14),(1.14 ±0.17) and (1.05 ±0.15),while the BMD of the control group were (0.84 ± 0.14),(0.86 ± 0.13),(0.92 ± 0.16) and (0.90 ± 0.13),and significant differences were found between the two groups (P ＜ 0.05).In the treatment group and thecontrol group,the serum BALP were (4.65 ± 1.23),(4.18 ± 1.03) μg · L-1,25-(OH)D3 were (39.83 ±5.52),(33.65 ±5.16) ng · mL-1,PINP were (336.68 ±28.36),(286.92 ±23.65) ng · mL-1,BGP were (14.86±2.86),(11.53±1.88) ng·mL-1,CTXwere (19.36±4.19),(14.65±3.67) μg· L-1,with statistically significant differences (P ＜ 0.05).The adverse drug reactions in treatment group was upper abdominal discomfort,the control group was facial flushing,the adverse drug reaction in control group and treatment group were 3.33％ (2/60 cases)and 1.67％ (1/60 case),the difference was not statistically significant (P ＞ 0.05).Conclusion The curative effect of 99Tc-MDP is significant in treatment of senile osteoporotic fracture and osteoarthriti,it can significantly improve the indexes of bone metabolism and increase bone density with high safety profile.
